AllDocs -> cancers

MJA Vol 177 1 July 2002 11 RESEARCH The Medical Journal of Australia ISSN: 0025-729X 1 July 2002 177 1 11-16 ©The Medical Journal of Australia 2002 www.mja.com.au Research I N V ICTORIA , OVARIAN CANCER is the sixth most common cancer in women, with an age-standardised incidence and mortality of 11.8 and 5.4 cases per 100 000 women, respectively. 1 The reported five-year survival for early- stage disease ranges from 50%–90%, and for late-stage disease from 55%– 20%. 2,3 The prognosis is worse in older women, those with advanced stage, ascites and poorly differentiated tumours or clear-cell adenocarcinoma. Poor prognoses are also associated with preoperative tumour rupture and dense adherence in early-stage disease, and with bulky ...

Abstract. Alternative splicing represents an important nuclear mechanism in the post-transcriptional regulation of gene expression, which is frequently altered during tumorigenesis. Previously, we have described marked changes in alternative splicing of the CD44 gene in ovarian and breast cancer . In the latter one we described also a specific induction of splicing factors during tumor development. Now we have focussed our studies on the expression profiles of splicing factors, including classical SR proteins, Tra2 and YB-1 in physio- logical and malignant ovarian tissues by RT-PCR and Western blot analysis. We detected changed expression pattern with higher levels of phosphorylated 30 kDa SR proteins as well as relatively high concentrations of hyperphosphorylated Tra2 protein isoforms in ovarian cancer . RT-PCR analysis revealed a marked induction of SC35 and ASF/SF2 as well as mRNA levels ...

REPORT OF THE NATIONAL OVARIAN CANCER FORUM Ovarian cancer : health service delivery supporting best practice Monday 16 th February 2004 Dockside Function Centre Cockle Bay Wharf Darling Park, Sydney, NSW G G y y n n a a e e c c o o l l o o g g i i c c a a l l C C a a n n c c e e r r R R e e s s e e a a r r c c h h F F u u n n d d Westmead Hospital Page 2 2 This report was prepared by the National Breast Cancer Centre: 92 Parramatta Road Camperdown, Sydney, Australia Locked Bag 16 Camperdown NSW 1450 Telephone +61 2 9036 3030 Facsimile +61 2 9036 3077 Website www.nbcc.org.au The Ovarian Cancer Program is funded by the Australian Government Department of Health and Ageing. Copies of the document can be downloaded from the National ...

A fact sheet from the Greater Bay Area Cancer Registry Ovarian Cancer in the Greater San Francisco Bay Area 1990-2000 Spring 2004 Cancer of the ovary is the fifth most common cause of cancer death among women in California. Based on the latest state cancer registry figures, 504 women were diagnosed and 290 died from ovarian cancer during 2000 in the Greater San Francisco Bay Area. Ovarian cancer incidence and mortality in our region have decreased slightly in the last ten years. Between 1990 and 2000, incidence and mortality rates have decreased approxi- mately 1-2% per year (below, Figure 1). Figure 1. Age-adjusted incidence and mortality rates for ovarian cancer by year of diagnosis, Greater San Francisco Bay Area, 1990-2000 0 2 4 6 8 10 12 14 16 18 20 1990 1991 1992 1993 1994 ...

102 Title 3—The President Proc. 7699 must make these programs available to more people. By providing vouchers that enable those struggling with addiction to get help from a wide range of sources that work, including faith-based and community organizations, we will expand treatment options and accountability. This flexibility will strengthen our system and offer more hope to those in need. My Administration has taken important steps to cut off illegal drug sup- plies and reduce demand through anti-drug education. For those who be- come addicted to drugs or to alcohol, my Administration is committed to tearing down the stigma attached to recovery so that more people will seek the help they need. Alcohol addiction and drug addiction are diseases that touch all Americans—young and old, rich and poor, male and female. As a Nation, we must continue our efforts to offer the best possible opportuni- ...

Increased Risk of Ovarian Cancer Is Linked to Estrogen Replacement Therapy Posted Date: Tuesday, July 16, 2002 Researchers from the National Cancer Institute (NCI) have found that women in a large study who used estrogen replacement therapy after menopause were at increased risk for ovarian cancer . The report was published in the July 17, 2002, issue of JAMA .* The scientists followed 44,241 women for approximately 20 years. Compared to postmenopausal women not using hormone replacement therapy, users of estrogen-only therapy had a 60 percent greater risk of developing ovarian cancer . The risk increased with length of estrogen use. The women, who were followed from 1979 to 1998, were former participants in the Breast Cancer Detection Demonstration Project, a mammography screening program conducted between 1973 and 1980. "The main finding of our study was that postmenopausal women ...

FY03 Ovarian Cancer Research Program Peer Reviewers Aldaz, Claudio M.D., Ph.D. Department of Carcinogenesis, UT MD Anderson Cancer Center Baker, Vicki M.D. Obstetrics and Gynecology Dept, Wayne State University Bar-Eli, Menashe Ph.D. Cancer Biology, UT MD Anderson Cancer Center Batra, Surinder Ph.D. Dept of Biochemistry and Molecular Biology, Univ of Nebraska Medical Ctr., Eppley Cancer Ctr Beattie, Craig Ph.D. Department of Animal Biotechnology, University of Nevada- Reno Beck, William Ph.D. Department of Biopharmaceutical Sciences, University of Illinois at Chicago Benbrook, Doris Ph.D. Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center Britten, Richard Ph.D. Department of Radiation Oncology, Eastern Virginia Medical School Cannon, Martin Ph.D. ...

Promotional/Educational Materials Order Form “Maintain Your Gynecologic Health with Education Please send me __ copies each & Early Detection” Brochure (English/Spanish) Circle one. Ovarian Cancer National Resource List Brochure Please send me __ copies each (English/Spanish) Circle one. “Beating The Odds” Brochure Please send me __ copies each Ad Slick Promoting 1/800-444-4441 Information Hotline (8.5” x 11”) Please send me __ copies each Ad Slick Featuring The Talk Show Hosts of The View (8.5” x 11”) Please send me __ copies each Poster Featuring The Talk Show Hosts of The View (16 x 14) Please send me __ copies each Ad Slick Featuring Miss USA/Miss USA Tent Card Please send me __ copies each Cervical Cancer Awareness Month Tent Card Please send me __ copies each Women’s Cancer Network Web ...

Abstract. The current studies represent the first step in assessing the utility of harringtonine in combination with cisplatin as an improved approach for treating ovarian cancer . Three ovarian cancer cell lines, platinum-sensitive A2780, and platinum-resistant A2780/CP70 and OvCar-3, were exposed to their respective IC 50 dose of cisplatin for 1 h with or without a 24-h pretreatment with harringtonine. The level of platinum-DNA adducts was determined by atomic absorption spectrometry (AAS). These studies show for the first time that harringtonine pretreatment significantly increased the amount of platinum-DNA adducts in all ovarian cancer cell lines by 2-4 fold, immediately following 1-h exposure to cisplatin. Moreover, the level of cisplatin-DNA adducts in harringtonine-pretreated cells remained elevated by 3-4.7-fold for at least 6 h after cisplatin was removed, relative ...

HERA Ovarian Cancer Climb for Life | http://ovariancancer.jhmi.edu/climb Where the Money Goes: Conquering Ovarian Cancer One Foot at a Time THE NEED q Ovarian cancer is not an uncommon disease. It is the 5th leading cause of cancer death among women and kills more women than all the other reproductive cancers combined. q 90% of women who get the disease have no family history q According to a recent study published in England, ovarian cancer is on the rise in younger women. q There is not a reliable test for ovarian cancer like the pap smear for cervical cancer or the mammogram for breast cancer . Over 78% of the women diagnosed in 2004 will be diagnosed after the disease has spread when the chance for survival is less than 20%. When ovarian cancer is caught early it is highly curable. By investing in ...

a report by Bristol-Myers Squibb Company Survival from ovarian cancer has increased over time mainly due to improvements in diagnosis, surgery and chemotherapy but, despite these advances, it remains the second most common and deadly form of gynaecological cancer with an overall five-year survival rate of less than 50%. 1 The evolution of chemotherapy regimens from standard platinum- based first-line chemotherapy to Taxol ® (paclitaxel) and cisplatin * as the standard of care has undoubtedly played a huge part in shaping a better landscape for women with this disease. We are all too aware of the devastating impact that any cancer has on the lives patients and their families, but ovarian cancer in particular can take everyone by surprise due to vague or silent symptoms associated with early stages of the disease, ...

Ovarian Cancer Product List by Organization Provided by Page 2 You were just diagnosed with ovarian cancer . Where do you turn? Numerous organizations are committed to informing, helping and supporting the over 25,000 women diagnosed with ovarian cancer each year. You will be offered a vast amount of information regarding the diagnosis, treatment and survivorship from family, friends and medical professionals. With so much information out there, how can you ensure you are getting exactly what you want and need? To sort through all of the information and help you identify the important data, the Gynecologic Cancer Foundation has created this user-friendly resource guide to summarize the information, prod- ucts and materials offered by leading ovarian cancer organizations. This patient directed non-product biased list includes national organizations that ...

September 2003, Vol. 32 No. 5 661 Bowel Surgery for Epithelial Ovarian Cancer —Y N Chia et al Bowel Surgery for Epithelial Ovarian Cancer – An Early Case Series Y N Chia,* MBBS, MRCOG (UK) , E H Tay,** M Med (O&G), MRCOG (UK), DGO (Aust-NZ) , D M O Cheong,*** FAMS, MBBS, FRCS (Glas) , K W Eu,**** FAMS, FRCS (Edin), M Med (Surg) , J Low, + FAMS, M Med (O&G), MRCOG (UK) , T H Ho, ++ FAMS, M Med (O&G), FRCOG (Lond) , K L Yam, +++ FAMS, M Med (O&G), FRCOG (Lond) Abstract Objectives: The aims of this study were to review our local experience with bowel surgery for epithelial ovarian cancer at the Gynaecological Cancer Centre, KK Women’s and Children’s Hospital, and to document the outcome of such surgery as well as their complication ...

Page 1 of 9 Coverage Position Number: 0321 C IGNA H EALTH C ARE C OVERAGE P OSITION Subject Stem-Cell Transplant for Ovarian Cancer Revised Date ..4/15/2006 Original Effective Date .4/15/2005 Coverage Position Number . 0321 Table of Contents Coverage Position..1 General Background .1 Coding/Billing Information..7 References.8 Hyperlink to Related Coverage Positions INSTRUCTIONS FOR USE Coverage Positions are intended to supplement certain standard CIGNA HealthCare benefit plans. Please note, the terms of a participant’s particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard ...

Original Article · Originalarbeit Key Words Epithelial ovarian cancer · DNA ploidy · Cytoreductive surgery · Chemotherapy · Survival time Summary Background: Most of the time, prognostic factors of patients with epithelial ovarian cancer (EOC) have been evaluated in hospital- based populations, mostly in secondary or tertiary referral centers. The aim of the study was to analyze these factors in a well-defined and nonselected population with complete follow-up from a can- tonal cancer registry and to assess the adequacy of treatment in an area which has no central institution for oncological treatment. Patients and Methods: From 1989 to 1995, the cantonal cancer regis- try of the Valais has registered 73 patients with ovarian epithelial cancers of stages III and IV; 72 patients have been evaluable. We have calculated survival rates and analyzed variables such ...

OVARIAN CANCER AWARENESS MONTH WHEREAS: Ovarian cancer has long been called a “silent killer,” because it occurs in an organ deep in the pelvis and produces vague symptoms that may be dismissed; and WHEREAS: Recent studies have identified factors that put women at higher risk of developing ovarian cancer , such as a family history of breast and ovarian cancer , no pregnancies or infertility, no history of oral contraceptive use, or the use of high-dose estrogen for long periods without progesterone; and WHEREAS: Early detection remains the most valuable weapon against ovarian cancer ; however, there is not a simple early detection method. Subtle symptoms include pelvic and abdominal pressure; bloating; pain, swelling or discomfort; unexpected weight gain or loss, especially weight gain in the abdominal area; gastrointestinal problems; and back pain and fatigue. ...

126 Title 3—The President Proc. 7587 Proclamation 7587 of August 30, 2002 National Ovarian Cancer Awareness Month, 2002 By the President of the United States of America A Proclamation During National Ovarian Cancer Awareness Month, Americans renew their commitment to learning more about the causes of this deadly disease, so that we can detect it early and treat it effectively. Ovarian cancer continues to cause more deaths than any other cancer of the female reproductive system. It is estimated that this year alone, more than 23,000 women in the United States will be diagnosed with ovarian cancer , and that almost 14,000 women will die from this disease. In cases where ovarian cancer is found and treated in its earliest stages, the 5-year survival rate is 95 percent. However, most women who suffer from this cancer are not diagnosed until it ...

Indian Journal of Clinical Biochemistry, 2003 27 Author for Corrospondence: Dr. Vinita Thakur Sr. Biochemist Biochemistry Unit, Department of Laboratory Medicine, Batra Hospital & Medical Research centre 1,Tughlakabad Institutional Area,MB Road, New Delhi 110062,India . Tel : 26080228, 22448083 Fax : 26087661, 26082455 Email : vthakur 57@ hotmail.com DETERMINATION OF CANCER ANTIGEN 125 IN OVARIAN CARCINOMA V. Thakur*, A.K. Anand **, U. Mukherjee* and D. Ghosh** *Department of Lab Medicine, **Department of Oncology, Batra Hospital & Medical Research Centre, New Delhi, India. 110062. ABSTRACT Appropriate therapeutic measures can improve the life expectancy of patients with ovarian malignancy.There has been a pressing need for serodiagnostic assays to enable the close patient monitoring. Cancer Antigen 125 (CA125) has been described as a useful ...

676 Annals Academy of Medicine Ovarian Cancer Screening—N D MacDonald et al Screening for Ovarian Cancer N D MacDonald,* MBBS (Hons) , A N Rosenthal,* BSc (Hons), MBBS , I J Jacobs,** MD, MRCOG Abstract Ovarian cancer is predominantly a disease of postmenopausal women which presents at a late stage and has an overall 5-year survival of less than 30%. If detected at stage I, survival is dramatically increased and this would suggest that screening for ovarian cancer may reduce mortality. However, the inaccessibility of the ovaries and the absence of a confirmed premalignant condition make screening for preclinical disease difficult. Recent advances in tumour marker interpretation and ultrasound technology have now allowed screening for ovarian cancer to become a real possibility. CA 125 is the most widely used tumour ...

Peer Reviewers 1 FY00 Ovarian Cancer Research Program Peer Reviewers Peer Reviewer Degree Institution/Affiliation Artemov, Dmitri Ph.D. Department of Radiology, Division of Magnetic Resonance Research, The Johns Hopkins University School of Medicine Atwood, Jan R. Ph.D., M.P.H., R.N., F.A.A.N. University of Nebraska Medical Center Bachur, Nicholas R. M.D., Ph.D. Department of Medicine, University of Maryland Cancer Center Bandera, Christina A. M.D. Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine Beattie, Craig W. Ph.D. Department of Veterinary Medicine, University of Nevada, Reno Boothman, David A. Ph.D. Department of Radiation Oncology, Case Western Reserve University Boyd, Jeffrey A. Ph.D. Departments of Surgery and Human Genetics, Memorial Sloan- Kettering ...

FY02 Ovarian Cancer Research Program Peer Reviewers Bai, Wenlong Ph.D. Baron, Andre T. Ph.D. Biochemistry and Molecular Biology, Mayo Clinic Foundation Batra, Surinder K. Ph.D. Dept. of Biochemistry and Molecular Biology, Univ of Nebraska Medical Ctr., Eppley Cancer Ctr Beck, William T. Ph.D. Department of Biopharmaceutical Sciences, University of Illinois at Chicago Benbrook, Doris M. Ph.D. Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center Bieberich, Charles J. Ph.D. Department of Biological Sciences, University of Maryland Baltimore County Bigbee, William L. Ph.D. Cancer Epidemiology Program, University of Pittsburgh Cancer Institute Blay, Jonathan Ph.D. Dept of Pharmacology, Dalhousie University Faculty of Medicine Bouhassira, Eric E. Ph.D. ...

FY01 Ovarian Cancer Research Program Peer Reviewers Almeida-Porada, Maria Graca D. M.D., Ph.D. Department of Medicine, VA Medical Center Bandera, Christina A. M.D. Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine Batra, Surinder Kumar Ph.D. Department of Biochemistry & Molecular Biology, University of Nebraska Medical College Beattie, Craig W. Ph.D. Department of Animal Biotechnology, University of Nevada- Reno Bigbee, William L. Ph.D. Dept. of Environmental & Occupational Health, University of Pittsburgh Cancer Institute Bourguignon, Lilly Y. W. Ph.D. VA Medical Center, University of California-San Francisco Boyd, Jeffrey A. Ph.D. Departments of Surgery and Human Genetics, Memorial Sloan Kettering Cancer Center Carney, James P. Ph.D. RORL, University ...

1 Peer Reviewers FY99 Ovarian Cancer Research Program Peer Reviewers Peer Reviewer Degree Institution/Affiliation Ackerman, Virginia M. Ovarian Cancer National Alliance Alexander, Doreene W. Southern New Mexico Cancer Support Services, Inc. Ambrosone, Christine B. Ph.D. Division of Molecular Epidemiology, National Center for Toxicological Research, Federal Drug Administration Andre, Michael P. Ph.D. Department of Radiology, University of California at San Diego Armstrong, Deborah K. M.D. Department of Medical Oncology, Johns Hopkins Oncology Center Ascensao, Joao L. M.D., Ph.D. Department of Internal Medicine, University of Nevada School of Medicine Bourguignon, Lilly Y. W. Ph.D. Department of Cell Biology and Anatomy, University of Miami Medical School Boyd, Jeffrey A. Ph.D. Departments ...

FY98 Ovarian Cancer Research Program Peer Reviewers Peer Reviewer Degree Institution/Affiliation Ackerman, Virginia Consumer Alvarez, Ronald M.D. Department of Obstetrics/Gynecology, University of Alabama at Birmingham Artemov, Dmitri Ph.D. Department of Radiology, The Johns Hopkins University School of Medicine Barton, Michelle Ph.D. Department of Molecular Genetics, University of Cincinnati Berchuck, Andrew M.D. Duke University Medical Center Bernstein, Jonine Ph.D. Department of Community and Preventive Medicine, Mount Sinai School of Medicine Bienstock, Rachelle Ph.D. National Institute of Environmental Health Sciences Boothman, David Ph.D. Departments of Radiation Oncology and Pharmacology, Case Western Reserve University Braly, Patricia M.D. Department of Obstetrics and Gynecology, ...

Abstract. Rad52 encodes a protein which is required for recombinational repair of double-strand breaks. It is also associated with breast cancer predisposition genes BRCA1 and BRCA2 . Mutations in the genes Rad51 or Rad52 result in severe defects in genetic recombination and the repair of double-strand DNA breaks. In order to examine if Rad52 mutations might be involved in sporadic ovarian cancer , we analyzed two stop mutations (Ser346ter and Tyr415ter) in 142 Austrian ovarian carcinoma patients and 128 healthy volunteers. In addition, we analyzed these two mutations in 105 breast/ ovarian cancer families (160 members) to examine if the mutations in Rad52 are associated with the occurrence of cancer and with mutations in the BRCA1 and BRCA2 genes. Our results show that these two mutations are rare in all three groups examined. There are no statistically significant differences ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com * Findings were statistically significant (strong evidence) + Evidence of a dose-response relationship (strongest evidence) Page 80 Ovarian Cancer and Exposure to Ionizing Radiation Summary : There has been moderately strong evidence recorded of a possible connection between ovarian cancer and exposure to ionizing radiation. This possible connection is supported by evidence from studies conducted at Los Alamos National Laboratory and other studies of nuclear workers at other sites who have been exposed to ionizing radiation. The National Research Council’s has determined that there is evidence among atomic bomb survivors of ovarian cancer in connection with exposure to ionizing radiation. Ovarian cancers are ...

Ovarian Cancer WHAT IS OVARIAN CANCER ? The ovaries are two small, almond-shaped organs located on either side of the uterus (the hollow muscular organ, commonly called the womb, in which the fetus develops). They are key components of a woman's reproductive system: Ovaries store between 200,000 and 400,000 follicles, tiny sacs, present from birth, that nurture immature eggs, or ova. • During each normal (usually monthly) reproductive cycle, a follicle in one ovary bursts and releases a mature or "ripened" egg. The egg travels down the fallopian tube into the uterus, where it either is fertilized by a man's sperm or, if unfertilized, breaks down and is excreted as part of the menstrual cycle. • Ovaries also secrete the important reproductive hormones estrogen and progesterone. • Ovarian Cancers Ovarian cancers are potentially life-threatening malignancies, ...

Descriptive Epidemiology of Ovarian Cancer in the United States, 1992-1997 CANCER (Supplement) 2003(May15);97/10:2615-2706. Descriptive Epidemiology of Ovarian Cancer in the United States, 1992-1997 Marc T. Goodman and Holly L. Howe Ovarian cancer is relatively uncommon, and therefore little has been published to date regarding racial or ethnic variations in the incidence or mortality of this malignancy. As the U.S. population becomes more diverse, the interest in health problems and disparities in outcomes among minority and economically disadvantaged groups will continue to increase. In this supplement, the authors focus on epidemiology, pathology and classification issues, multiple primary tumors, staging, and incidence and mortality for race/ethnic groups. The authors also focused on epidemiologic differences between borderline tumors of low malignant potential and carcinomas. ...

Teal We Meet Again Announces Ongoing Donation Campaign for Ovarian Cancer Teal We Meet Again, an online based webstore, is a spin-off of Alyssa’s Soap Cottage. What started as a handmade bath and body business, branched out into a new site that donates proceeds from each and every product to Ovarian Cancer awareness. Plano, TX (PRWEB) January 10, 2005 –- Teal We Meet Again would like to invite you to help support Ovarian Cancer awareness and education. Teal We Meet Again is the home of handmade bath and body products, including soaps and lotions, all in the fragrance that was created especially for their Fragrance for a Cause line, Whispering Angels. You can also find handmade Swarovski crystal bracelets, jewelry, ornaments, stuffed animals, magnets and jelly bracelets, to name a few. A percentage of all sales, ranging from 10% up to 100% is donated to two organizations, National Ovarian ...

Revised 3/4/02 C/Ke documents/ /Patient Info on Fertility Drugs and Ovarian Cancer Kutteh Ke Fertility Associates of Memphis, PLLC 80 Humphreys Center, Suite 307 Memphis, TN 38120 T: 901.747.2229 F: 901.747.4446 www.fertilitymemphis.com Patient Fact Sheet Infertility, Fertility Drugs, and Ovarian Cancer Many couples faced with infertility are treated with ovulation induction medications, often referred to as fertility drugs. These medications (such as clomiphene citrate) may help a patient to ovulate who previously was not ovulating or, when given empirically, may induce one or two more follicles to be produced each cycle than the customary one. The second class of fertility drugs (gonadotropins) are usually given as some form of an injection and will induce the timed release of multiple eggs in one cycle. These medications are commonly combined with ...